AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
4min chapter
Big Pharma | The Gillett Health Podcast #34
The Gillett Health Podcast
The Heterogeneity of Compounding Pharmacies
A lot of the trials for vasoactive intestinal peptide and it's a bit different for this they're looking for. I believe late in 2022, it received its not emergency use authorization but it received its fast track to be a drug for Disney fast pass. So you can slice and dice the data a million different ways. There's a lot of heterogeneity with compounding pharmacies. And there's another potential polyfill VIP with migraine bed. You combine the nasal sprays. This is true. The one that described itself as a phase two B slash three trial. Not sure exactly why, but we thought we'd take note of that. Is it two B or is it not two B
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode